IPSC · Century Therapeutics, Inc.
$2.24
+0.05 (+2.28%)
At close · Jul 21
Market Cap
$403.99M
Shares
180.35M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$109.16M
+1556.8%
FY2025
Net Income
-$9.58M
+92.4%
FY2025
Operating Margin
-15.82%
+2080.7pp
FY2025
Diluted EPS
-$0.14
+91.3%
FY2025
Operating Cash Flow
-$103.88M
+5.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| — | $109.16M | $6.59M | $2.24M | $5.2M | — | — | |
| $86.19M | $95.67M | $107.24M | $92.71M | $97.17M | $75.65M | $39.68M | |
| $22.17M | $24M | $33.16M | $34.71M | $31.86M | $19.24M | $9.5M | |
| $115.13M | $126.43M | $144.73M | $148.78M | $139.03M | $94.88M | $53.9M | |
| -$115.13M | -$17.27M | -$138.14M | -$146.55M | -$133.83M | -$94.88M | -$53.9M | |
| — | -15.82% | -2096.48% | -6556.87% | -2574.17% | — | — | |
| — | — | — | $540K | $1.02M | $1.28M | $381K | |
| $7.28M | $7.62M | $13.36M | $11.75M | $2.99M | -$898K | $323K | |
| — | -$9.65M | -$124.78M | -$134.79M | -$130.84M | -$95.78M | -$53.58M | |
| — | -$68K | $1.79M | $1.88M | $91K | $43K | — | |
| -$107.79M | -$9.58M | -$126.57M | -$136.67M | -$130.93M | -$95.82M | -$53.58M | |
| — | -8.78% | -1920.87% | -6115.12% | -2518.41% | — | — | |
| -$108.68M | -$9.87M | -$126.35M | -$134.1M | -$132.74M | -$96.47M | -$53.58M | |
| USD/shares | — | -$0.14 | -$1.61 | -$2.30 | -$2.27 | -$2.96 | -$7.16 |
| USD/shares | — | -$0.14 | -$1.61 | -$2.30 | -$2.96 | -$2.96 | -$7.16 |
| shares | — | 86.56M | 78.65M | 59.31M | 57.76M | 32.39M | 7.48M |
| shares | — | 86.56M | 78.65M | 59.31M | 32.39M | 32.39M | 7.48M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.68×
EV/EBIT
—
Biotechnology median 26.45×
P/E (TTM)
—
Biotechnology median 7.21×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Single Reportable Segment | $109,164,000 | $6,589,000 | $2,235,000 |